Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of Drugs in Dermatology|
|State||Published - Jun 1 2010|
ASJC Scopus subject areas